MLL gene amplification in acute myeloid leukemia and myelodysplastic syndromes is associated with characteristic clinicopathological findings and TP53 gene mutation

Human Pathology

Volumn 46, Issue 1, 2015, Pages 65-73

  Tang, Guilin ^a   Dinardo, Courtney ^a   Zhang, Liping ^a   Ravandi, Farhad ^a   Khoury, Joseph D ^a   Huh, Yang O ^a   Muzzafar, Tariq ^a   Medeiros, L Jeffrey ^a   Wang, Sa A ^a   Bueso Ramos, Carlos E ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

AML MDS; Cytogenetics; MLL amplification; Pathologic features; TP53 mutation

Indexed keywords

DNA METHYLTRANSFERASE 3A; MIXED LINEAGE LEUKEMIA PROTEIN; NOTCH1 RECEPTOR; PROTEIN P53; HISTONE LYSINE METHYLTRANSFERASE; MLL PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLOOD CLOTTING DISORDER; BONE MARROW CELL; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CELL NUCLEUS; CELL VACUOLE; CHROMOSOME 11; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; DISSEMINATED INTRAVASCULAR CLOTTING; DYSERYTHROPOIESIS; DYSPLASIA; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; IMMUNOPHENOTYPING; KARYOTYPE; LEUKEMIA CELL; MALE; MONOCYTE MACROPHAGE PRECURSOR CELL; MYELOBLAST; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; TREATMENT RESPONSE; COMPLICATION; DNA MUTATIONAL ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC PREDISPOSITION; GENETICS; HUMAN CHROMOSOME; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MORTALITY; MUTATION; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; PHENOTYPE; RETROSPECTIVE STUDY; RISK FACTOR; TIME FACTOR; TREATMENT FAILURE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOMES, HUMAN; DNA MUTATIONAL ANALYSIS; FEMALE; GENE AMPLIFICATION; GENETIC PREDISPOSITION TO DISEASE; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; MYELOID-LYMPHOID LEUKEMIA PROTEIN; PHENOTYPE; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT FAILURE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84915819184     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2014.09.008     Document Type: Article

References (35)

1. M. Schwab Oncogene amplification in solid tumors Semin Cancer Biol 9 1999 319 325
2. I. Sarova, J. Brezinova, and Z. Zemanova Cytogenetic manifestation of chromosome 11 duplication/amplification in acute myeloid leukemia Cancer Genet Cytogenet 199 2010 121 127
3. A. Herry, N. Douet-Guilbert, and N. Gueganic Del(5q) and MLL amplification in homogeneously staining region in acute myeloblastic leukemia: a recurrent cytogenetic association Ann Hematol 85 2006 244 249
4. H. Avet-Loiseau, C. Godon, and J.Y. Li Amplification of the 11q23 region in acute myeloid leukemia Genes Chromosomes Cancer 26 1999 166 170
5. Y. Ariyama, Y. Fukuda, and Y. Okuno Amplification on double-minute chromosomes and partial-tandem duplication of the MLL gene in leukemic cells of a patient with acute myelogenous leukemia Genes Chromosomes Cancer 23 1998 267 272
6. B. Streubel, P. Valent, and U. Jager Amplification of the MLL gene on double minutes, a homogeneously staining region, and ring chromosomes in five patients with acute myeloid leukemia or myelodysplastic syndrome Genes Chromosomes Cancer 27 2000 380 386
7. R.W. Maitta, L.A. Cannizzaro, and K.H. Ramesh Association of MLL amplification with poor outcome in acute myeloid leukemia Cancer Genet Cytogenet 192 2009 40 43
8. G. Cuthbert, K. Thompson, and S. McCullough MLL amplification in acute leukaemia: a United Kingdom Cancer Cytogenetics Group (UKCCG) study Leukemia 14 2000 1885 1891
9. J.C. Pajuelo-Gamez, J. Cervera, and Z. Garcia-Casado MLL amplification in acute myeloid leukemia Cancer Genet Cytogenet 174 2007 127 131
10. L. Michaux, I. Wlodarska, and M. Stul MLL amplification in myeloid leukemias: a study of 14 cases with multiple copies of 11q23 Genes Chromosomes Cancer 29 2000 40 47
11. M. Dolan, R.C. McGlennen, and B. Hirsch MLL amplification in myeloid malignancies: clinical, molecular, and cytogenetic findings Cancer Genet Cytogenet 134 2002 93 101
12. B. Poppe, J. Vandesompele, and C. Schoch Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies Blood 103 2004 229 235
13. K. Tanaka, M. Takechi, S. Nishimura, N. Oguma, and N. Kamada Amplification of c-MYC oncogene and point mutation of N-RAS oncogene point mutation in acute myelocytic leukemias with double minute chromosomes Leukemia 7 1993 469 471
14. M.K. Andersen, D.H. Christiansen, M. Kirchhoff, and J. Pedersen-Bjergaard Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents Genes Chromosomes Cancer 31 2001 33 41
15. A. Zatkova, S. Merk, and M. Wendehack AML/MDS with 11q/MLL amplification show characteristic gene expression signature and interplay of DNA copy number changes Genes Chromosomes Cancer 48 2009 510 520
16. F. Racke, C. Cole, A. Walker, J. Jones, and N.A. Heerema Therapy-related pro-B cell acute lymphoblastic leukemia: report of two patients with MLL amplification Cancer Genet 205 2012 653 656
17. J. Jaso, D.A. Thomas, and K. Cunningham Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B-lymphoblastic leukemia in the era of tyrosine kinase inhibitors Cancer 117 2011 4009 4017
18. L.G. Shaffer, J. McGowan-Jordan, and M. Schmid An international system for human cytogenetic nomenclature Recommendations of the international standing committee on human cytogenetic nomenclature 2013 S. Karger Basel
19. R. Luthra, K.P. Patel, and N.G. Reddy Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring Haematologica 99 2014 465 473
20. R. Kanagal-Shamanna, C.E. Bueso-Ramos, and B. Barkoh Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53 Cancer 118 2012 2879 2888
21. M. Warren, R. Luthra, and C.C. Yin Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients Mod Pathol 25 2012 1405 1412
22. J.W. Vardiman, D.A. Arber, and R.D. Brunning Therapy-related myeloid neoplasms WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008 International Agency for Research on Cancer Lyon
23. J.M. Bennett, D. Catovsky, and M.T. Daniel Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group Br J Haematol 33 1976 451 458
24. J.L. Hess, B.D. Yu, B. Li, R. Hanson, and S.J. Korsmeyer Defects in yolk sac hematopoiesis in MLL-null embryos Blood 90 1997 1799 1806
25. C. Meyer, J. Hofmann, and T. Burmeister The MLL recombinome of acute leukemias in 2013 Leukemia 27 2013 2165 2176
26. P.M. Ayton, and M.L. Cleary Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9 Genes Dev 17 2003 2298 2307
27. C.A. Felix, M.D. Megonigal, and D.S. Chervinsky Association of germline p53 mutation with MLL segmental jumping translocation in treatment-related leukemia Blood 91 1998 4451 4456
28. L.M. Secker-Walker General report on the European Union concerted action workshop on 11q23, London, UK, May 1997 Leukemia 12 1998 776 778
29. A. Guarini, L. Gugliotta, and C. Timoncini Procoagulant cellular activity and disseminated intravascular coagulation in acute non-lymphoid leukaemia Scand J Haematol 34 1985 152 156
30. S. Alvarez, and J.C. Cigudosa Gains, losses and complex karyotypes in myeloid disorders: a light at the end of the tunnel Hematol Oncol 23 2005 18 25
31. C. Schoch, W. Kern, A. Kohlmann, W. Hiddemann, S. Schnittger, and T. Haferlach Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile Genes Chromosomes Cancer 43 2005 227 238
32. J.L. Lai, C. Preudhomme, and M. Zandecki Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations Leukemia 9 1995 370 381
33. F.G. Rucker, R.F. Schlenk, and L. Bullinger TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome Blood 119 2012 2114 2121
34. L.R. Livingstone, A. White, J. Sprouse, E. Livanos, T. Jacks, and T.D. Tlsty Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53 Cell 70 1992 923 935
35. Y. Yin, M.A. Tainsky, F.Z. Bischoff, L.C. Strong, and G.M. Wahl Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles Cell 70 1992 937 948